Navigation Links
Telik Implements Reorganization to Focus Resources Toward Drug Development Pipeline

PALO ALTO, Calif., Feb. 11 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) announced today that it is implementing a reorganization to focus on its most advanced preclinical and clinical drug development programs. The reorganization will enable the company to continue the development of TELINTRA(R) and the two leading preclinical drug candidates: a prodrug cytotoxic, TLK58747, and dual Aurora-VEGFR kinase inhibitor, TLK60404.

The restructuring will involve a workforce reduction of 44% primarily in early-stage discovery and support positions. Employees directly affected by the restructuring plan will receive severance payments, continuation of benefits and outplacement assistance. The company estimates incurring personnel-related restructuring charges of approximately $0.9 million in the first quarter of 2009.

"This reorganization will allow us to focus our resources on the clinical development of our lead compound, TELINTRA, currently in Phase 2 Studies for Myleodysplastic Syndrome and Chemotherapy Induced Neutropenia, as well as other potential indications. We also plan to advance our two leading preclinical drug candidates and continue to support our TRAP(R) technology collaborations," said Michael Wick, M.D., Ph.D., Chairman and Chief Executive Officer. "We are thankful for the significant contributions our employees have made."

Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer and inflammatory diseases. The company's most advanced investigational drug candidates in clinical development are TELINTRA, a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA(R), a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP, which enables the rapid and efficient discovery of small molecule drug candidates.

This press release contains "forward-looking" statements, including but not limited to statements with respect to the amount and timing of expected restructuring charges relating to the reorganization plan, and the continuing development of TELINTRA and preclinical drug candidates. Any statements herein that are not statements of historical fact may be deemed to be forward-looking statements. There are a number of important factors that could cause results to differ materially from those indicated by these forward-looking statements, including, among others, risks and uncertainties related to Telik's ability to obtain the capital necessary to fund its continuing operations on acceptable terms or to enter into a third party collaboration to develop, manufacture and commercialize our products, the possibility that the Company may require more cash than anticipated for its operating activities, the Company's need to retain skilled employees and consultants, and other risks detailed from time to time in the Company's SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2008, and other periodic filings with the SEC. The Company does not undertake any obligation to update forward-looking statements.

TELIK, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.

SOURCE Telik, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Telik Announces New TRAP Drug Discovery Agreement
2. Telik Announces Financial Results for 2008 Third Quarter
3. Telik Announces Top-Line Results From Assist-5 Trial of Telcyta(R) in Combination With Pegylated Liposomal Doxorubicin in Platinum Refractory and Resistant Ovarian Cancer
4. Telik Announces 2008 Third Quarter Financial Release, Conference Call and Webcast
5. Telik Announces Receipt of Nasdaq Notice
6. Teliks Aurora Kinase-VEGFR Dual Inhibitor Program Meets a Preclinical Development Milestone
7. ReceptorBio Announces Diabetes License Agreement With Telik
8. Telik Announces Financial Results For 2008 Second Quarter
9. Telik Announces 2008 Second Quarter Financial Release, Conference Call and Webcast
10. Telik Announces Publication of Diabetes Research in Bioorganic & Medicinal Chemistry Letters
11. Telik Announces Presentation and Webcast at Needham Biotechnology Conference
Post Your Comments:
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... of a new, Good Manufacturing Practice (GMP) 10000 in the Santiago Marriott. The ... available, and is operated by a world-class team of qualified medical researchers and ...
(Date:11/30/2015)... December 1, 2015 Partnership includes an ... for the u niversity , s ... treatment s cale - up ...   Africa , where licensees based anywhere in the world ... SDN technology. --> Africa , where licensees based anywhere in ...
(Date:11/30/2015)... , Nov. 30, 2015 Spherix ... company committed to the fostering and monetization of ... current and prospective initiatives designed to create shareholder ... Executive Officer of Spherix. "Based on published reports, ... licensees exceeds $50 billion and Spherix will seek ...
(Date:11/30/2015)... 30, 2015 TapImmune, Inc. ... of innovative peptide and gene-based immunotherapeutics and vaccines for ... it will be presenting at the 8 th ... at 2.30 PM PT. Dr. John N. Bonfiglio ... be giving the presentation and will join TapImmune management ...
Breaking Biology Technology:
(Date:10/29/2015)... YORK , Oct. 29, 2015 ... technology, announced a partnership with 2XU, a global ... to deliver a smart hat with advanced bio-sensing ... and other athletes to monitor key biometrics to ... the strategic partnership, the two companies will bring together ...
(Date:10/27/2015)... October 27, 2015 Munich, ... Gaze Mapping technology (ASGM) automatically maps data from mobile ... Glasses , so that they can be quantitatively ... Munich, Germany , October 28-29, 2015. ... data from mobile eye tracking videos created with ...
(Date:10/26/2015)... 26, 2015 ... adds Biometrics Market Shares, Strategies ... well as Emerging Biometrics Technologies: Global ... its collection of IT and Telecommunications ... --> . ...
Breaking Biology News(10 mins):